Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation.
Recruiting
N/A
Interventional Study
Obesity
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 45 – 60
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 33 (estimated)
- Sponsor
- University of North Carolina, Chapel Hill · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if daily supplementation with SPM Active® can increase omega 3 polyunsaturated fatty acid derivatives and improve well-being in adults with obesity. The main questions it aims to answer are:
Does 2 g/day of SPM Active® for 12 weeks increase plasma levels of 14-hydroxydocosahexaenoic (HDHA), 17-HDHA, and 18-hydroxy eicosapentaenoic acid (HEPE)?
Does 2 g…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* adults, ages 45-60 years
* Body mass index (BMI) between 30 and 40 kg/m\^2
* Any race or ethnicity
Exclusion Criteria:
* Age \< 45 years or \> 60 years
* pregnant or breastfeeding women
* BMI \< 30 kg/m\^2 or \> 40 kg/m\^2
* Diagnosed type 1 or type 2 diabetes
* Active autoi…
Contacts